News

Stocktwits on MSN8d
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...
MyChesCo on MSN7d
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Fierce Pharma7d
Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...
Nasdaq9d
Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...